-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III

Program: Oral and Poster Abstracts
Type: Poster
Monday, December 13, 2021: 6:00 PM-8:00 PM
Hall B5, Level 1, Building B (Georgia World Congress Center)

Guillermo Garcia-Manero, MD1, Aaron D Goldberg, MD, PhD2, Eric S. Winer, MD3, Jessica K. Altman, MD4, Amir T. Fathi, MD5, Olatoyosi Odenike, MD6, Gail J. Roboz, MD7, Phillip Gallacher8*, Anders Wennborg, MD, PhD8*, Denice Kaylor Hickman, BSN, RN8*, Eyal C. Attar, MD8 and David A. Sallman, MD9

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Memorial Sloan Kettering Cancer Center, New York, NY
3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
4Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
5Massachusetts General Hospital Cancer Center, Boston, MA
6Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL
7Division of Hematology Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY
8Aprea Therapeutics, Boston, MA
9Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL

Sonja Loges, MD, PhD1*, Michael Heuser, MD2, Jörg Chromik, MD3*, Grerk Sutamtewagul, MD4, Silke Kapp-Schwoerer, MD5*, Monica Crugnola, MD6*, Nicola Di Renzo, MD7*, Roberto M. Lemoli, MD8, Daniele Giovanni Mattei, MD9, Isabel Ben Batalla, PhD10,11*, Monica Hellesøy, MS, PhD12*, Jonas Waizenegger, M.D.11*, Lisa-Marie Rieckmann, M.Sc13*, Melanie Janning, MD11,14*, Charles D. Imbusch, PhD15*, Niklas Beumer, M.Sc16*, Austin Rayford, M.Sc17*, Jaya Nautiyal, PhD18*, Tzivia Berkman-Gottlieb, MSc19*, David Micklem, PhD20*, Hani Gabra, MD, PhD, FRCPE, FRCP18*, Claudia Gorcea-Carson, MD21*, James B. Lorens, PhD22*, Walter Fiedler, MD23, Yesid Alvarado, MD24 and Bjorn T. Gjertsen, MD, PhD25

1Universitätsklinikum Mannheim, Mannheim, Germany
2Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
3Medical Clinic II, Hematology, Hemostaseology, Medical Oncology, Rheumatology, Infectious Disease, University Hospital Frankfurt, Frankfurt, Germany
4Department of Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA
5Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
6Hematology and BMT Center, Department of Medicine and Surgery, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
7Department of Hematology and Stem Cell Transplant, Presidio Ospedaliero Vito Fazzi, Lecce, Italy
8University of Genoa, Genoa, Italy
9Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy
10German Cancer Research Center (DKFZ), University of Mannheim, Mannheim, Germany
11Department of Personalised Oncology, University Medical Center Mannheim, Mannheim, Germany
12Department of Internal Medicine, Hematology section, Haukeland University Hospital, Bergen, Norway
13German Cancer Research Center (DKFZ), Heidelberg, Germany
14German Cancer Research Center (DKFZ), Heidelberg, Heidelberg, Germany
15Division of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany
16Department of Personalised Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
17BerGenBio ASA, Bergen, Norway
18Translational Biomarkers, BerGenBio ASA, Oxford, United Kingdom
19Data Analysis, BerGenBio ASA, Oxford, United Kingdom
20Translational Biomarkers, BerGenBio ASA, Bergen, Norway
21BerGenBio ASA, Oxford, United Kingdom
22Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway
23Universitätsklinik Hamburg-Eppendorf, Hamburg, Germany
24Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
25Haukeland University Hospital, Bergen, Norway

Maro Ohanian, DO1*, Martha L. Arellano, MD2, Moshe Y. Levy, MD3, Kristen O'Dwyer, MD4, Hani Babiker, MD5*, Daruka Mahadevan, MD, PhD6, Hongying Zhang, MD, PhD7*, Nasrin Rastgoo, PhD7*, Yuying Jin, PhD7*, Jotin Marango, MD., Ph.D.7*, Stephen B Howell, MD8, William G Rice, PhD7 and Rafael Bejar, MD, PhD7,8

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
3Baylor University Medical Center, Dallas, TX
4University of Rochester Medical Center, Rochester, NY
5Department of Medicine, The University of Arizona Cancer Center, Tucson, AZ
6UTH Health San Antonio, MD Anderson Cancer Center, San Antonio, TX
7Aptose Biosciences, Inc., San Diego, CA
8Moores Cancer Center, University of California San Diego Health, La Jolla, CA

Gary J. Schiller, MD1, Laura Finn, MD2, Gail J. Roboz, MD3, Johnnie J. Orozco, MD, PhD4, Tiffany Lin5*, Mary M Chen, MD6 and Mohamed M. Hegazi, MD7*

1David Geffen School of Medicine at UCLA, Los Angeles, CA
2Ochsner Medical Center, New Orleans, LA
3Division of Hematology Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY
4Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
5Actinium Pharmaceuticals, Inc., New York, NY
6Actinium Pharmaceuticals, Inc, New York, MD
7James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY

Linjie Tian1*, Ana Paucarmayta1*, Rustin Lovewell1*, Karla Maloveste1*, Junshik Hong, MD2,3, Carly Hedgepath2*, Kwang Woon Kim2*, Ron Copeland1*, Thomas O’Neill1*, Shashank Patel1*, Linda N. Liu, PhD1*, Han Myint, MD, FRCPath, FRCP1, Solomon Langermann, PhD1*, Dallas B Flies1* and Tae Kon Kim, MD2

1NextCure, Inc., Beltsville, MD
2Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN
3Department of Internal Medicine, Seoul national university hospital, Seoul, Korea, Republic of (South)

Sameem Abedin, MD1, Guru Subramanian Guru Murthy, MD1*, Mehdi Hamadani, MD2, Laura C. Michaelis, MD1, Lyndsey Runaas, MD1*, Karen Carlson, MD, Ph.D.1* and Ehab L. Atallah, MD3

1Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
2BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI
3Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

Justin M Watts, MD1,2, Tara L. Lin, MD3,4, Alice S. Mims, MD5,6, Prapti Patel, MD7, Paul J Shami, MD8,9, Elizabeth H. Cull, MD10, Christopher R. Cogle, MD11, Cynthia Lee, PhD12* and Fatih Uckun, MD, PhD12

1Sylvester Comprehensive Cancer Center, Miami, FL
2University of Miami Health System, Miami, FL
3Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas, Kansas City, KS
4University of Kansas Medical Center, Kansas City, KS
5Arthur G. James Cancer Center Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH
6Ohio State University Wexner Medical Center, Columbus, OH
7Division of Hematology Oncology, University of Texas Southwestern Medical Center, Dallas, TX
8Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
9Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
10GHS Cancer Institute, Greenville, SC
11Department of Medicine, University of Florida, Gainesville, FL
12Aptevo Therapeutics, Seattle

Tara L. Lin, MD1, Justin M Watts, MD2,3, Alice S. Mims, MD4,5, Prapti Patel, MD6, Paul J Shami, MD7,8, Elizabeth H. Cull, MD9,10, Christopher R. Cogle, MD11, Cynthia Lee, PhD12* and Fatih Uckun, MD, PhD12

1University of Kansas, Westwood, KS
2Sylvester Comprehensive Cancer Center, Miami, FL
3University of Miami Health System, Miami, FL
4The Ohio State University, Columbus, OH
5Arthur G. James Cancer Center Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH
6Division of Hematology Oncology, University of Texas Southwestern Medical Center, Dallas, TX
7Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
8Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
9GHS Cancer Institute, Greenville, SC
10Cancer Institute, Prisma Health, Piedmont, SC
11Department of Medicine, University of Florida, Gainesville, FL
12Aptevo Therapeutics, Seattle

Eytan M. Stein, MD1, Jörg Chromik, MD2*, Cecilia Carpio, MD3*, Rogier Mous, MD, PhD4*, Jean-Jacques Kiladjian, MD, PhD5, Gheath Alatrash, DO, PhD6, Antonio Curti, MD, PhD7, Charles Craddock, FRCP, FRCPath8, Christoph Schmid, MD9*, Robert Zeiser, MD10, Lamis K. Eldjerou, MD11, Hans-Jochen Jochen Weber, PhD12*, Claire Fabre, MD, PhD13, Jeffrey Scott, PhD11* and Daniel J. DeAngelo, MD, PhD14

1Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
2Department of Medical Oncology, Goethe Universitat Frankfurt, Frankfurt am Main, Germany
3Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
4Universitair Medisch Centrum Utrecht, Academic Medical Center, Utrecht, NH, Netherlands
5Hôpital Saint-Louis; Université de Paris, INSERM, Paris, France
6Department of Hematopoietic Biology & Malignancy, The University of Texas MD Anderson Cancer Center, Pearland, TX
7IRCCS Azienda ospedaliero-universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy
8Centre for Clinical Haematology, University Hospitals Birmingham, Birmingham, United Kingdom
9Department of Hematology and Oncology / Stem Cell Transplantation, Augsburg University Hospital and Medical Faculty, Augsburg, Germany
10Department of Medicine I Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
11Novartis Pharmaceuticals Corporation, East Hanover, NJ
12Novartis Pharma AG, Basel, Switzerland
13Novartis Pharmaceuticals Corporation, Basel, Switzerland
14Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA

Camille Abboud Sr., MD1,2, Gautam Borthakur, MD3, Scott R. Solomon, MD4, Howard A. Burris Sr., MD5, Terrence Bradley, MD6, JAN Maciej Zaucha Sr.7*, Ewa Lech-Marańda, MD, PhD8*, Krzysztof Brzozka, PhD9*, Tomasz Rzymski, PhD9*, Peter Littlewood, BSc10*, Elie Mouhayar, MD11*, Setareh Shamsili, MD, PhD9* and Noemi Angelosanto, MD9

1Division of Oncology, Washington University In Saint Louis;, Saint Louis, MO
2Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO
3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4Leukemia Program, Northside Hospital Cancer Center Institute, Atlanta, GA
5Sarah Cannon Research Institute, Nashville, TN
6University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL
7Medical University of Gdansk, Gdansk, Poland
8Institute of Hematology and Transfusion Medicine, Warsaw, Poland
9Ryvu Therapeutics, Cracow, Poland
10Ryvu Therapeutics, Krakow, Poland
11MDACC, Houston, TX

Sai Prasad Desikan, MD1*, Hagop Kantarjian, MD2, Courtney D. DiNardo, MD, MSCE2, Gautam Borthakur, MD3, Naval Daver, MD4, Naveen Pemmaraju, MD2, Yesid Alvarado, MD2, Jan A. Burger, MD, PhD5, Debra Bull Linderman, RN4*, Sherry A. Pierce, BSN, BA2*, Farhad Ravandi, MB Bs6, Guillermo Garcia-Manero, MD2 and Tapan M. Kadia, MD7

1Leukemia, MD Anderson, Houston, TX
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3MD Anderson Cancer Center, The University of Texas, Houston, TX
4MD Anderson Cancer Center, Houston, TX
5Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
6Department of Leukemia, The University of Texas MD Anderson Cancer Center, HOUSTON, TX
7Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX

Alice S. Mims, MD1, Melhem Solh, MD2, Jennifer N. Saultz, DO3, Uma Borate, MD4, Naveen Pemmaraju, MD5, Gautam Borthakur, MD5, Gail J. Roboz, MD6, Ben Powell, PhD7*, Bernice Matusow7*, Jason Halladay, PhD7*, Shireen Vali, PhD7*, Chelsea L. Hope, PhD7*, Madan G. Kundu, PhD8*, Ching Hsu, PhD8*, Paul Watkins7*, Chao Zhang, PhD7*, Jackie M. Walling, PhD, MD7, Athanasios C. Tsiatis, MD7 and Amy E. DeZern, MD9

1The Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH
2Northside Hospital Cancer Institute, Atlanta, GA
3Knight Cancer Institute, Oregon Health & Science University, Portland, OR
4The James Cancer Center, The Ohio State University, Columbus, OH
5Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
6Division of Hematology/Oncology, Department of Medicine, Weill Medical College of Cornell university, New York, NY
7Plexxikon Inc., Berkeley, CA
8Daiichi Sankyo, Basking Ridge, NJ
9Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

Naveen Pemmaraju, MD1, Kapil N. Bhalla, MD1, Naval Daver, MD2, Nathaniel R Wilson, MD3*, Warren C. Fiskus, BSc, PhD4, Farhad Ravandi, MB Bs5, Guillermo Garcia-Manero, MD1, Tapan M. Kadia, MD6, Courtney D. DiNardo, MD, MSCE1, Elias J. Jabbour7, Jan A. Burger, MD, PhD1, Nicholas Short, MD5, Yesid Alvarado, MD1, Nitin Jain, MD8, Lucia Masarova, MD4*, Srdan Verstovsek, MD, PhD6, Ghayas C. Issa, MD1, Wei Qiao, PhD9*, Joseph D. Khoury10, Sherry A. Pierce, BSN, BA1*, Darla Miller1*, Marina Konopleva, MD, PhD1, Hagop Kantarjian, MD1 and Gautam Borthakur, MD11

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2MD Anderson Cancer Center, Houston, TX
3Internal Medicine, The University of Texas Health Sciences Center at Houston, Houston, TX
4Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
5Department of Leukemia, The University of Texas MD Anderson Cancer Center, HOUSTON, TX
6Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX
7Department of Leukemia, University of Texas M.D. Anderson Cancer Ctr., Houston, TX
8Department of Leukemia, MD Anderson Cancer Center, Houston, TX
9Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
10Department of Hematopathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
11MD Anderson Cancer Center, The University of Texas, Houston, TX

Andrius Zucenka1,2*, Vilmantė Vaitekėnaitė, MD1*, Kazimieras Maneikis, MD1*, Regina Pileckytė, MD, PhD1,2*, Igoris Trociukas, MD1*, Valdas Pečeliūnas, MD, PhD1,2* and Laimonas Griškevičius, MD, PhD1,2*

1Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
2Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania

Marina Konopleva, MD, PhD1, Danielle M. Brander, MD2, Krish Patel3*, Catherine S. Diefenbach, MD4, Yesid Alvarado, MD5, Olga Frankfurt, MD6*, Monzr M. Al Malki, MD7, Alexey V. Danilov, MD, PhD8,9, Sameem Abedin, MD10, Kebede H. Begna, MD11, Avyakta Kallam, MD12, Richard G. Ghalie, MD, MBA13 and Matthew S. Davids, MD14

1The University of Texas MD Anderson Cancer Center, Houston, TX
2Duke Cancer Institute, Duke University Medical Center, Durham, NC
3Swedish Cancer Institute, Seattle, WA
4New York University, New York, NY
5Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
6Northwestern University, Chicago, IL
7Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA
8City of Hope Toni Stephenson Lymphoma Center, Duarte, CA
9City of Hope Comprehensive Cancer Center, Duarte, CA
10Blood & Marrow Transplantation and Cellular Therapy Program, Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
11Divison of Hematology, Mayo Clinic, Rochester, MN
12Division of Hematology & Oncology, Department of Internal Medicine, University of Nebraska Medical Center- Fred and Pamela Buffett Cancer Center, Omaha, NE
13MEI Pharma, San Diego, CA
14Dana-Farber Cancer Institute, Boston, MA

Paresh Vyas, DPhil, FRCP, FRCPath, MRCP, MRCPath1,2, Naval Daver, MD3, Mark Chao, MD, PhD4, Guan Xing, PhD4*, Camille Renard, MSc4*, Giri Ramsingh, MD4*, Andrew H. Wei, MD, PhD5 and David A. Sallman, MD6

1MRC Molecular Hematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
2MRC Molecular Haematology Unit and Oxford Biomedical Research Centre, University of Oxford and Oxford University Hospitals, Oxford, United Kingdom
3The University of Texas MD Anderson Cancer Center, Houston, TX
4Gilead Sciences, Inc., Foster City, CA
5Department of Haematology, Alfred Hospital and Monash University, Melbourne, Australia
6Moffitt Cancer Center, Tampa, FL

Sung-Soo Yoon, MD1, Dong-Yeop Shin, MD, PhD2*, Je-Hwan Lee, MD, PhD3, Jun Ho Jang, MD, PhD4, June-Won Cheong, MD, PhD5, Ho-Jin Shin, MD, PhD6*, Jeong-Ok Lee, MD Ph.D.7, Yunsuk Choi, MD., Ph.D.8*, Anish Puliyayil, MD. DM. FRACP.9*, Joseph Clarey, MBBS FRACP FRCPA10*, Jeejin Im11*, Ky-Youb Nam, PhD11*, Kyu-Tae Kim, PhD11*, June Han11*, Jeong-Hyeok Yoon, PhD.11*, Bao Nguyen12*, Li Li, MD., PhD.12* and Donald Small, MD., PhD.12

1Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
2Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)
3Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of (South)
4Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)
5Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, KOR
6Department of Internal Medicine, Pusan National University Hospital, Busan, Korea, Republic of (South)
7Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South)
8Department of Hematology and Oncology, Ulsan University Hospital, Ulsan, Korea, Republic of (South)
9Border Medical Oncology and Haematology, Albury-Wodonga Cancer Centre, Albury, Australia
10ICON caner centre, North Mackay, Australia
11Pharos iBio Co., Ltd., Anyang, Korea, Republic of (South)
12Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD

Naval Daver, MD1, Paresh Vyas, DPhil, FRCP, FRCPath, MRCP, MRCPath2, Mark Chao, MD, PhD3, Guan Xing, PhD3*, Camille Renard, MSc3*, Giri Ramsingh, MD3*, David A. Sallman, MD4 and Andrew H. Wei, MD, PhD5

1The University of Texas MD Anderson Cancer Center, Houston, TX
2Weatherall Institute of Molecular Medicine, Weatherall Inst. of Molecular Medicine, Oxford, United Kingdom
3Gilead Sciences, Inc., Foster City, CA
4Moffitt Cancer Center, Tampa, FL
5Department of Haematology, Alfred Hospital and Monash University, Melbourne, Australia

*signifies non-member of ASH